Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer
The invention provides an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide for treatment of cancer is provided. A method of treating cancer using the IGF-1 receptor ligand carrying a therapeutic radionuclide is also provided. An anti-cancer therapeutic agent containing an IGF-1 receptor ligand linked to a toxin is also provided, as are methods of using the toxin conjugates for treatment of cancer.
1. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand linked to a toxin;
wherein the IGF-1 receptor ligand comprises a polypeptide sequence at least 90% identical to SEQ ID NO:1;
wherein the toxin comprises Clostridium perfringens enteroxin residues 45-116 of SEQ ID NO:4.
2. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand linked to a toxin;
wherein the IGF-1 receptor ligand comprises SEQ ID NO:2;
wherein the toxin comprises Clostridium perfringens enteroxin residues 45-116 of SEQ ID NO:4.
3. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand linked to a toxin;
wherein the IGF-1 receptor ligand comprises a polypeptide sequence at least 90% identical to SEQ ID NO:1;
wherein the toxin comprises diphtheria toxin residues 1-193 of SEQ ID NO:5.
4. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand linked to a toxin;
wherein the IGF-1 receptor ligand comprises a polypeptide sequence at least 90% identical to SEQ ID NO:1;
wherein the toxin comprises ricin chain A.
5. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand linked to a toxin;
wherein the IGF-1 receptor ligand comprises SEQ ID NO:2;
wherein the toxin comprises diphtheria toxin residues 1-193 of SEQ ID NO:5.
6. An anti-cancer therapeutic agent comprising:
an insulin-like growth factor-1 (IGF-1) receptor ligand linked to a toxin;
wherein the IGF-1 receptor ligand comprises SEQ ID NO:2;
wherein the toxin comprises ricin chain A.